Antimicrobial Resistance in South Asian Aquaculture Is a Trade Problem Now, Not Just a Health One
Antibiotic use in shrimp and fish farming across Bangladesh and India is driving resistance patterns that increasingly show up in human infections. Export markets are starting to notice, which changes who has leverage to fix it.
Antimicrobial resistance has been called a slow pandemic for years, and the language has mostly failed to move policy at the pace the problem deserves. What is moving policy, unexpectedly, is trade. As importing countries tighten residue testing on seafood, aquaculture-heavy economies across South Asia are discovering that AMR mitigation is no longer just a public health recommendation. It's a market access requirement.
The resistance pathway runs through the water
Shrimp and finfish aquaculture across Bangladesh, India, and Sri Lanka relies heavily on antibiotic use to manage disease pressure in high-density farming systems. Resistant bacteria move from farmed water systems into surrounding waterways, into food supply chains, and eventually into clinical settings, where they complicate treatment of common infections. This is a textbook One Health pathway: environmental antibiotic pressure creating resistance that shows up in a completely different sector months or years later.
What makes this moment different is that the economic incentives are starting to point in the same direction as the public health ones. Buyers in the EU, Japan, and increasingly the US are tightening antibiotic residue thresholds on imported seafood, and farms that can't meet them lose access to the highest-value markets.
Why this is a diplomacy opportunity, not just a compliance burden
Framed only as a compliance cost, antibiotic reduction in aquaculture is a hard sell to smallholder farmers operating on thin margins. Framed as a market access strategy, with technical and financing support attached, it becomes a proposition governments can actually sell to their own agricultural sectors.
This is where regional trade bodies, exporting-country governments, and importing-country regulators have room to build something more durable than a standard compliance mandate: joint investment in on-farm diagnostics, alternative disease management practices, and traceability systems that let compliant farms differentiate themselves in the market. That kind of joint investment only happens when someone is doing the unglamorous work of aligning ministries of health, agriculture, and trade around a shared implementation plan.
The next two years matter
Resistance patterns don't reverse quickly, but market requirements can tighten fast. Countries that get ahead of the compliance curve, with real farm-level implementation rather than paper policy, will hold onto premium export markets. Countries that treat this as a future problem will find themselves negotiating from a weaker position when the next round of import restrictions arrives.